Shares of Wave Life Sciences WVE surged 74.1% on Wednesday after the company reported positive proof-of-mechanism data from ...

Wave Life Sciences (WVE) shares rallied 74.1% in the last trading session to close at $14.90. This move can be attributable ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

People who buy the stock today are thus exposed to a high risk of their shares getting diluted. That's in addition to the ...

Wave Life Sciences in a Tuesday filing with the SEC said Takeda has elected to terminate its option to continue work on ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

Wave Life Sciences (NASDAQ:WVE – Get Free Report) had its price objective upped by Leerink Partners from $20.00 to $22.00 in ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...

Shares of Wave Life Sciences WVE surged 74.1% on Wednesday after the company reported positive proof-of-mechanism data from an ongoing early to mid-stage study of its investigational candidate ...